



NanoStar

Pharmaceuticals

Mission

To enable novel therapeutics by developing innovative targeted drug delivery technologies.

Core technologies

Cellax: a polysaccharide-drug conjugate platform technology that targets water insoluble drugs to tumors. It prolongs the pharmacokinetics and increases drug delivery to specific tumors, leading to tumor regression and extended survival.

HepHoming: a proprietary lipid nanoparticle formulation that targets payloads to hepatocytes.

iBoost: a proprietary lipid nanoparticle formulation that localizes a toll-like receptor agonist in the tumor microenvironment and promotes antigen delivery to dendritic cells, which results in localized priming of the tumor microenvironment and development of specific antitumor immunity—leading to cures.

NanoStar specializes in nanoparticle drug delivery technologies.

We synthesize novel polymers and lipids, and use innovative engineering techniques to formulate drugs into nanoparticles that can target specific tissues and cells.

We focus on drugs that are challenged with delivery issues and diseases that are poorly treated with available medications.

NanoStar is currently focusing on addressing liver cancer, pancreatic cancer and the peritoneal metastases of cancers.

NanoStar's proprietary technologies transform delivery-challenged drugs into safe, effective, and novel therapies to address unmet medical needs.

nanostarpharma.com

Drug Delivery >> Targeted

NanoStar's technologies target the delivery of investigational drugs to those parts of the body where they can exert their novel pharmacological effects.

Leadership



Star Li

Co-Founder & CEO



Angel Lee

Co-Founder & COO

NanoStar
Pharmaceuticals Ltd.

2405 Wesbrook Mall, RM#5519,
Vancouver, BC Canada V6T1Z3

angel.lee@nanostarpharma.com
nanostarpharma.com